Charles River Laboratories (CRL) Announces Avian Vaccine Divestiture
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Charles River Labs (CRL) PT Raised to $250 at Jefferies
November 3, 2022 8:14 AM EDTJefferies analyst David Windley raised the price target on Charles River Labs (NYSE: CRL) to $250.00 (from $240.00) while maintaining a Buy rating.
The analyst commented, "In broad strokes, the composition of CRL's strong report was as we expected in our upgrade. Consolidated... More
Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance
November 2, 2022 7:06 AM EDTCharles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.63, $0.09 better than the analyst estimate of $2.54. Revenue for the quarter came in at $989.2 million versus the consensus estimate of $974.65 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $10.80-$10.95, versus the consensus of... More
